Connect with us
Prague Gaming & TECH Summit 2024

Artificial Intelligence

Global Footwear Industry

Published

on

New York, April 07, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Footwear Industry” – https://www.reportlinker.com/p05151473/?utm_source=GNW
Other major factors driving growth in the market include rise of smart concepts such as connected fabrics, footwear internet of things and material innovations including leather alternatives derived from fruit, palm, mushroom, pineapple and sericin. 3D printing is increasingly becoming mainstay of shoe manufacturing with the technology enabling manufacturers to cope with the overwhelming demand for a wide variety of shoe designs and mass customization. In the casual footwear market, timeless classics are making a comeback with women preferring simple classic black pair of shoes with medium heels which serve as perfect accessory for almost any outfit. From office to date to gym, people are buying footwear for every occasion. Shoes are increasingly becoming expressive of one’s personality, a trend that is driving up the concept of “investment shoes” defined as expensive shoes with luxury materials such as premium leather. Sneakers are rapidly going from street fashion into the sophisticated corporate boardrooms. In a landmark change in consumer behavior, men are spending more shoes and are preferring color over the conventional black. Consumerism is the key reason behind the growing per capita consumption of footwear worldwide. Other noteworthy trends in the market include growing popularity of dimethylformamide (DMF) free PU synthetic leather chemicals in the manufacture of footwear supported by benefits such as design freedom and environmental benefits; increased consumer involvement in sports and fitness activities and the ensuing demand for athletic footwear; and growing commercial value of eco-friendly footwear and increased research and development interest in plant-based leathers. The rise of multifunctional fashion is driving the prominence of convertible shoes interchangeable with a wide range of dresses. Also, emerging and established footwear brands are resorting to celebrity endorsements to help spur sales of non-athletic footwear.
– Athletic shoes constitute one of the leading categories of the footwear market, supporting the active lifestyles of consumers who are increasingly getting ’sporty’. Key footwear brands within the segment include Nike and adidas as well as small-sized brands and companies that offer a wide range of footwear for diverse customer segments. Companies operating within the segment are also constantly innovating on functionality, performance and comfort to evade competition. From golfing to running, sports have become highly intertwined with consumers’ day-to-day lifestyles and are not considered just recreation. Growing awareness of keeping fit, both among the ageing and the youngsters, is bolstering healthy growth, coupled with rising average per capita income. In what is being considered as a relatively new trend, gifting of athletic footwear on prominent occasions and holidays is fast catching up across the US and other markets. In the past couple of years, footwear has earned itself as one of the most sought after holiday gifts, thereby making it one of the top five preferences for local consumers. This particular trend is expected to boost growth of the local footwear industries in the US and developed European market. The United States, in value terms, represents the single largest market worldwide supported by robust demand for athletic and sporting footwear as a result of their acceptance as part of casual dressing among men and women. Asia-Pacific including China is a major market led by factors such as growing population, apparel needs and a parallel increase in demand for affordable mass-market footwear; westernization of lifestyles among young affluent people and a parallel increase in demand for sneakers; and growing preference for high-fashion and branded footwear among the middle class population.

Select Competitors (Total 470 Featured) –

  • adidas AG
  • Reebok International Limited
  • ANTA Sports Products Limited
  • ASICS Corporation
  • Bata
  • Bata India Ltd.
  • Caleres
  • Deckers Brands
  • ECCO Sko A/S
  • Feng Tay Enterprises Co., Ltd.
  • Geox s.p.a
  • Gucci Group NV
  • Kenneth Cole Productions, Inc.
  • LaCrosse Footwear, Inc.
  • Nike Inc.
  • Nine West
  • Power Athletics Limited
  • Puma SE
  • RG Barry Corporation
  • Timberland LLC
  • Vans, Inc.
  • Weyco Group Inc.
  • Wolverine World Wide, Inc.

Read the full report: https://www.reportlinker.com/p05151473/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
EXHIBIT 1: The World of Clinical Microbiology Gains Sudden
Prominence as Scientists Mobilize United Efforts to Find Ways
to Detect, Treat & Vaccinate People Against the Novel
Coronavirus: Global Scale of Daily Testing Vs Confirmed
Cases Per Million
Clinical Microbiology: An Introduction
Outlook: Evolutionary Battle against Microbes Drives Market Future
Instant Detection of Pathogens : A New Epoch in the Fight for
Survival
Reagents Account for Major Share
Asia-Pacific Drives Future Growth
Recent Market Activity
World Brands

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Microbiology Laboratories Switch to Automation to Push Yields
EXHIBIT 2: World Laboratory Automation Market in US$ Billion
for Years 2018, 2020, 2022, 2024 & 2026
Clinical Microbiology Market Benefits from Digitalization and
Robotization Trend
Integration of Clinical Microbiology with Cloud Computing
Artificial Intelligence Holds Positive Implications for
Automation of Clinical Microbiology
Advancements in Molecular Diagnostics Drive Market Growth
Emerging Technologies in Clinical Microbiology Diagnostics Aim
at Faster Diagnosis
Technological Advances Crucial to Sustain Future Market Growth
Rapid Diagnostics Bring in a Transformation
Automated and Rapid Microbiological Tests Revolutionize
Microbiological Testing
Traditional Rapid Microbiological Tests Make Way for New, Probe
Tests
Antibiotic Resistant Bacteria Throws the Spotlight on Microbial
Testing
Research in Stem Cell Technology, and Regenerative Medicine
Expand Growth Opportunities
EXHIBIT 3: Stem Cell Banking Global Market Estimates and
Forecasts in US$ Billion: 2020, 2022 & 2024
Greater Number of Tests for HIV and Sexually Transmitted
Diseases Amplify Growth
EXHIBIT 4: Global HIV Prevalence: Number of People Living with
AIDs (in Thousands) by Region for 2018
EXHIBIT 5: Number of AIDS-Related Deaths (in Thousands) by
Region for 2018
Rapid HIV Tests: A New Age Diagnostic Weapon against the Killer
Disease
Home HIV Testing Emerges as a Lucrative Option
Increasing Incidence of Infectious Diseases Drives Growth
EXHIBIT 6: Infectious Diseases Remain Major Cause of Death in
Under Developed Regions: Breakdown of Leading Causes of Death
in Sub-Saharan Africa (in %)
EXHIBIT 7: Infectious Diseases Related Mortality High Among
Children Below 5 Years: Breakdown of Leading Causes of Death
in Children Below 5 Years (in %)
Increasing Prevalence of Respiratory Infections Drive Growth
EXHIBIT 8: Global Number of Deaths Caused Due to Communicable
Diseases (In 000s)
Influenza Boosts Rapid Test Prospects
EXHIBIT 9: Flu Related CDC Estimates from October 2019-April4,
2020
Rise in Prevalence of COPD Augments Demand
EXHIBIT 10: Global Prevalence of COPD by Age Group: Percentage
of Men and Women Affected by the Condition
Rise in Pollution Levels Trigger Increase in Respiratory Diseases
EXHIBIT 11: World Ranking of Most Polluted Countries: 2019
EXHIBIT 12: Percentage Share Breakdown of Global Deaths Linked
to Air Pollution
Increase in Healthcare Spending in Emerging Markets to Propel
Demand
EXHIBIT 13: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023
Demographic Shifts & Societal Changes Drive Demand for Test
Volumes
EXHIBIT 14: Elderly Healthcare Expenditure as a % of GDP
EXHIBIT 15: Global Population Statistics for the 65+ Age Group
in Million by Geographic Region for the Years 2019, 2025, 2035
and 2050
EXHIBIT 10: Life Expectancy at Age 60 and 80 Years: (2010-2015
), (2020-2025) & (2045-2050)

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Geographic Region –
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Clinical Microbiology
Instruments and Reagents by Geographic Region – USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Geographic Region – Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Instruments by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Instruments by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Instruments by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Reagents by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Reagents by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Reagents by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Respiratory
Diseases by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Respiratory Diseases by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Respiratory Diseases by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Bloodstream
Infections by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Bloodstream Infections by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Bloodstream Infections
by Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Gastrointestinal
Diseases by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Gastrointestinal Diseases
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Gastrointestinal
Diseases by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 19: World Current & Future Analysis for Sexually
Transmitted Diseases by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Sexually Transmitted
Diseases by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Sexually Transmitted
Diseases by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 22: World Current & Future Analysis for Urinary Tract
Infections by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Urinary Tract Infections by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Urinary Tract
Infections by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 25: World Current & Future Analysis for Other Disease
Areas by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 26: World Historic Review for Other Disease Areas by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Other Disease Areas by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Hospitals &
Diagnostic Centers by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Hospitals & Diagnostic
Centers by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Hospitals & Diagnostic
Centers by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 31: World Current & Future Analysis for Custom Lab
Service Providers by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Custom Lab Service
Providers by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Custom Lab Service
Providers by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 34: World Current & Future Analysis for Academic &
Research Institutes by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 35: World Historic Review for Academic & Research
Institutes by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Academic & Research
Institutes by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

III. MARKET ANALYSIS

UNITED STATES
Market Overview
EXHIBIT 16: Healthcare Spending as a % of GDP in the US: 2010-2020
COVID-19 Pandemic: US Emerges as a Major Market for COVID-19 Tests
Table 37: USA Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Product – Instruments
and Reagents – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Clinical Microbiology
Instruments and Reagents by Product – Instruments and Reagents
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Product – Percentage Breakdown of
Value Sales for Instruments and Reagents for the Years 2012,
2020 & 2027

Table 40: USA Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Disease Area –
Respiratory Diseases, Bloodstream Infections, Gastrointestinal
Diseases, Sexually Transmitted Diseases, Urinary Tract
Infections and Other Disease Areas – Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 41: USA Historic Review for Clinical Microbiology
Instruments and Reagents by Disease Area – Respiratory
Diseases, Bloodstream Infections, Gastrointestinal Diseases,
Sexually Transmitted Diseases, Urinary Tract Infections and
Other Disease Areas Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Disease Area – Percentage Breakdown
of Value Sales for Respiratory Diseases, Bloodstream
Infections, Gastrointestinal Diseases, Sexually Transmitted
Diseases, Urinary Tract Infections and Other Disease Areas for
the Years 2012, 2020 & 2027

Table 43: USA Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by End-Use – Hospitals &
Diagnostic Centers, Custom Lab Service Providers and Academic &
Research Institutes – Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 44: USA Historic Review for Clinical Microbiology
Instruments and Reagents by End-Use – Hospitals & Diagnostic
Centers, Custom Lab Service Providers and Academic & Research
Institutes Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 45: USA 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by End-Use – Percentage Breakdown of
Value Sales for Hospitals & Diagnostic Centers, Custom Lab
Service Providers and Academic & Research Institutes for the
Years 2012, 2020 & 2027

CANADA
Table 46: Canada Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Product – Instruments
and Reagents – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Clinical Microbiology
Instruments and Reagents by Product – Instruments and Reagents
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Product – Percentage Breakdown of
Value Sales for Instruments and Reagents for the Years 2012,
2020 & 2027

Table 49: Canada Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Disease Area –
Respiratory Diseases, Bloodstream Infections, Gastrointestinal
Diseases, Sexually Transmitted Diseases, Urinary Tract
Infections and Other Disease Areas – Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 50: Canada Historic Review for Clinical Microbiology
Instruments and Reagents by Disease Area – Respiratory
Diseases, Bloodstream Infections, Gastrointestinal Diseases,
Sexually Transmitted Diseases, Urinary Tract Infections and
Other Disease Areas Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Disease Area – Percentage Breakdown
of Value Sales for Respiratory Diseases, Bloodstream
Infections, Gastrointestinal Diseases, Sexually Transmitted
Diseases, Urinary Tract Infections and Other Disease Areas for
the Years 2012, 2020 & 2027

Table 52: Canada Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by End-Use – Hospitals &
Diagnostic Centers, Custom Lab Service Providers and Academic &
Research Institutes – Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 53: Canada Historic Review for Clinical Microbiology
Instruments and Reagents by End-Use – Hospitals & Diagnostic
Centers, Custom Lab Service Providers and Academic & Research
Institutes Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 54: Canada 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by End-Use – Percentage Breakdown of
Value Sales for Hospitals & Diagnostic Centers, Custom Lab
Service Providers and Academic & Research Institutes for the
Years 2012, 2020 & 2027

JAPAN
Market Overview
Covid-19 Testing Market in Japan
Demographics Drive Market Growth
EXHIBIT 17: Breakdown of Population by Age Group in Japan:
2010, 2020, and 2025
Market Analytics
Table 55: Japan Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Product – Instruments
and Reagents – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Clinical Microbiology
Instruments and Reagents by Product – Instruments and Reagents
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Product – Percentage Breakdown of
Value Sales for Instruments and Reagents for the Years 2012,
2020 & 2027

Table 58: Japan Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Disease Area –
Respiratory Diseases, Bloodstream Infections, Gastrointestinal
Diseases, Sexually Transmitted Diseases, Urinary Tract
Infections and Other Disease Areas – Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 59: Japan Historic Review for Clinical Microbiology
Instruments and Reagents by Disease Area – Respiratory
Diseases, Bloodstream Infections, Gastrointestinal Diseases,
Sexually Transmitted Diseases, Urinary Tract Infections and
Other Disease Areas Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Disease Area – Percentage Breakdown
of Value Sales for Respiratory Diseases, Bloodstream
Infections, Gastrointestinal Diseases, Sexually Transmitted
Diseases, Urinary Tract Infections and Other Disease Areas for
the Years 2012, 2020 & 2027

Table 61: Japan Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by End-Use – Hospitals &
Diagnostic Centers, Custom Lab Service Providers and Academic &
Research Institutes – Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 62: Japan Historic Review for Clinical Microbiology
Instruments and Reagents by End-Use – Hospitals & Diagnostic
Centers, Custom Lab Service Providers and Academic & Research
Institutes Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 63: Japan 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by End-Use – Percentage Breakdown of
Value Sales for Hospitals & Diagnostic Centers, Custom Lab
Service Providers and Academic & Research Institutes for the
Years 2012, 2020 & 2027

CHINA
Market Overview
Covid-19 Testing Market
Market Analytics
Table 64: China Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Product – Instruments
and Reagents – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 65: China Historic Review for Clinical Microbiology
Instruments and Reagents by Product – Instruments and Reagents
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 66: China 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Product – Percentage Breakdown of
Value Sales for Instruments and Reagents for the Years 2012,
2020 & 2027

Table 67: China Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Disease Area –
Respiratory Diseases, Bloodstream Infections, Gastrointestinal
Diseases, Sexually Transmitted Diseases, Urinary Tract
Infections and Other Disease Areas – Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 68: China Historic Review for Clinical Microbiology
Instruments and Reagents by Disease Area – Respiratory
Diseases, Bloodstream Infections, Gastrointestinal Diseases,
Sexually Transmitted Diseases, Urinary Tract Infections and
Other Disease Areas Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Disease Area – Percentage Breakdown
of Value Sales for Respiratory Diseases, Bloodstream
Infections, Gastrointestinal Diseases, Sexually Transmitted
Diseases, Urinary Tract Infections and Other Disease Areas for
the Years 2012, 2020 & 2027

Table 70: China Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by End-Use – Hospitals &
Diagnostic Centers, Custom Lab Service Providers and Academic &
Research Institutes – Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 71: China Historic Review for Clinical Microbiology
Instruments and Reagents by End-Use – Hospitals & Diagnostic
Centers, Custom Lab Service Providers and Academic & Research
Institutes Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 72: China 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by End-Use – Percentage Breakdown of
Value Sales for Hospitals & Diagnostic Centers, Custom Lab
Service Providers and Academic & Research Institutes for the
Years 2012, 2020 & 2027

EUROPE
Market Overview
COVID-19 Pandemic Propels Demand
Growth in Clinical Diagnostics Automation
Rise in Automated, and Rapid Tests in Clinical Applications
Ageing Demography: An Opportunity Indicator
Market Analytics
Table 73: Europe Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Geographic Region –
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Clinical Microbiology
Instruments and Reagents by Geographic Region – France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Geographic Region – Percentage
Breakdown of Value Sales for France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Product – Instruments
and Reagents – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Clinical Microbiology
Instruments and Reagents by Product – Instruments and Reagents
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Product – Percentage Breakdown of
Value Sales for Instruments and Reagents for the Years 2012,
2020 & 2027

Table 79: Europe Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Disease Area –
Respiratory Diseases, Bloodstream Infections, Gastrointestinal
Diseases, Sexually Transmitted Diseases, Urinary Tract
Infections and Other Disease Areas – Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 80: Europe Historic Review for Clinical Microbiology
Instruments and Reagents by Disease Area – Respiratory
Diseases, Bloodstream Infections, Gastrointestinal Diseases,
Sexually Transmitted Diseases, Urinary Tract Infections and
Other Disease Areas Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Disease Area – Percentage Breakdown
of Value Sales for Respiratory Diseases, Bloodstream
Infections, Gastrointestinal Diseases, Sexually Transmitted
Diseases, Urinary Tract Infections and Other Disease Areas for
the Years 2012, 2020 & 2027

Table 82: Europe Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by End-Use – Hospitals &
Diagnostic Centers, Custom Lab Service Providers and Academic &
Research Institutes – Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 83: Europe Historic Review for Clinical Microbiology
Instruments and Reagents by End-Use – Hospitals & Diagnostic
Centers, Custom Lab Service Providers and Academic & Research
Institutes Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 84: Europe 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by End-Use – Percentage Breakdown of
Value Sales for Hospitals & Diagnostic Centers, Custom Lab
Service Providers and Academic & Research Institutes for the
Years 2012, 2020 & 2027

FRANCE
Table 85: France Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Product – Instruments
and Reagents – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 86: France Historic Review for Clinical Microbiology
Instruments and Reagents by Product – Instruments and Reagents
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 87: France 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Product – Percentage Breakdown of
Value Sales for Instruments and Reagents for the Years 2012,
2020 & 2027

Table 88: France Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Disease Area –
Respiratory Diseases, Bloodstream Infections, Gastrointestinal
Diseases, Sexually Transmitted Diseases, Urinary Tract
Infections and Other Disease Areas – Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 89: France Historic Review for Clinical Microbiology
Instruments and Reagents by Disease Area – Respiratory
Diseases, Bloodstream Infections, Gastrointestinal Diseases,
Sexually Transmitted Diseases, Urinary Tract Infections and
Other Disease Areas Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 90: France 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Disease Area – Percentage Breakdown
of Value Sales for Respiratory Diseases, Bloodstream
Infections, Gastrointestinal Diseases, Sexually Transmitted
Diseases, Urinary Tract Infections and Other Disease Areas for
the Years 2012, 2020 & 2027

Table 91: France Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by End-Use – Hospitals &
Diagnostic Centers, Custom Lab Service Providers and Academic &
Research Institutes – Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 92: France Historic Review for Clinical Microbiology
Instruments and Reagents by End-Use – Hospitals & Diagnostic
Centers, Custom Lab Service Providers and Academic & Research
Institutes Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 93: France 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by End-Use – Percentage Breakdown of
Value Sales for Hospitals & Diagnostic Centers, Custom Lab
Service Providers and Academic & Research Institutes for the
Years 2012, 2020 & 2027

GERMANY
Table 94: Germany Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Product – Instruments
and Reagents – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 95: Germany Historic Review for Clinical Microbiology
Instruments and Reagents by Product – Instruments and Reagents
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 96: Germany 15-Year Perspective for Clinical Microbiology
Instruments and Reagents by Product – Percentage Breakdown of
Value Sales for Instruments and Reagents for the Years 2012,
2020 & 2027

Table 97: Germany Current & Future Analysis for Clinical
Microbiology Instruments and Reagents by Disease Area –
Respiratory Diseases, Bloodstream Infections, Gastrointestinal
Diseases, Sexually Transmitted Diseases, Urinary Tract
Infections and Other Disease Areas – Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 98: Germany Historic Review for Clinical Microbiology
Instruments and Reagents by Disease Area – Respiratory
Diseases, Bloodstream Infections, Gastrointestinal Diseases,
Sexually Transmitted Diseases, Urinary Tract Infections and
Other Disease Areas Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05151473/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Invoca Wins CX Today Award for Best Conversational Intelligence Solution of 2024; Launches European Data Centre and Adds UK Sales Leader

Published

on

invoca-wins-cx-today-award-for-best-conversational-intelligence-solution-of-2024;-launches-european-data-centre-and-adds-uk-sales-leader

CX Today recognises Invoca as the foremost visionary in the Conversational Intelligence category. Additionally, expands its European presence with a new Data Centre and the appointment of Duncan MacPherson as UK Director of Sales.
LONDON, March 28, 2024 /PRNewswire/ — Invoca, the leading revenue execution platform for revenue teams, has won the CX Today Award for ‘Best Conversational Intelligence Solution’ of 2024. CX Today, the leading international news publication honouring excellence in CX technology, hosted the CX Awards to honour excellence in CX leadership, technology innovation, and industry success.

“Invoca’s exceptional work in conversational intelligence has helped push the category forward, and we are thrilled to see their accomplishments acknowledged at CX Awards 2024,” said Charlie Mitchell, Senior Editor at CX Today and host of the awards.
The award recognises Invoca’s strength in empowering revenue teams across marketing, contact centre sales, and customer experience to enhance buying experiences, increase high-value leads, and boost revenue. For businesses that acquire customers over the phone, Invoca enables these digital marketing and contact centre teams to collaborate to drive revenue growth. Invoca stands out for capturing deep insights from consumer calls and digital interactions and ingesting revenue driven by calls and other metadata from CRM and contact centre solutions, making Invoca the source of truth for consumer engagements.
“We’re thrilled to be named the Best Conversational Intelligence Solution of 2024 by CX Today as we highlight our longstanding vision to help brands acquire customers and grow their revenue,” said Gregg Johnson, CEO of Invoca. “As AI pioneers in this space, having first introduced our broad base of patented AI technologies in 2015, artificial intelligence and machine learning are core to helping companies improve the customer experience and connect the buyer journey.”
The CX Awards’ judging panel, including Dan Miller, Lead Analyst at Opus Research, reviewed hundreds of applications for their organisation’s ability to improve overall customer experience through innovation and high-impact features.
“Invoca continues to demonstrate that they are a clear leader in conversational intelligence AI. We recognised Invoca for their ability to employ a sophisticated blend of AI technologies — including patented machine learning, generative AI, voice biometrics, and deep learning neural networks, to drive revenue,” said Dan Miller, CX Awards judge and Lead Analyst at Opus Research.
Invoca Launches New European Platform and Data Centre Amid U.K. Sales Leadership Expansion
Invoca continues to reinforce its commitment to maintaining data excellence with unwavering reliability and strict adherence to security standards. Protecting customer data privacy remains a top priority, particularly given the heightened concerns surrounding security and privacy. Invoca’s new European platform and localised data centres support its growing customer base by ensuring all customers can adhere to the highest level of enterprise-grade data privacy, and GDPR compliance standards. Invoca’s powerful EU-based infrastructure enables its customers to recreate the same Invoca experience using the full feature suite while maintaining the highest standards of quality.
Invoca has also welcomed Duncan MacPherson as UK Director of Sales. MacPherson brings extensive experience with large companies and start-ups selling customer engagement solutions. This is part of an overall expansion in the UK market, which includes hiring a localised sales and customer success team, sales development, and marketing support.
More Information:
See the results you can get with Invoca’s award-winning conversation intelligence: https://www.invoca.com/customersInvoca’s GDPR Compliance: Everything You Need to Know: https://www.invoca.com/blog/invocas-gdpr-compliance-everything-you-need-to-knowWatch the CX Today Awards winners revealed on demand: www.cxtoday.com/cxawardsJoin Invoca’s talented team today: https://www.invoca.com/company/careersAbout InvocaInvoca is a revenue execution platform that connects marketing and sales teams to help them track and optimise the buying journey to drive more revenue. By using a comprehensive revenue execution platform with deep integrations with leading technology platforms, revenue teams can better connect their paid media investments directly to revenue, improve digital engagement, and deliver the best buyer experiences to drive more sales. With Invoca, top consumer brands, including AutoNation, DIRECTV, Mayo Clinic, Mutual of Omaha, and Verizon, experience unbelievable results powered by undeniable data. Invoca has raised $184M from leading venture capitalists, including Upfront Ventures, Accel, Silver Lake Waterman, H.I.G. Growth Partners, and Salesforce Ventures. For more information, visit www.invoca.com.
About CX AwardsHosted by CX Today, the awards ceremony has become the beacon of recognition for companies and professionals pushing the envelope in the CX technology sphere.
The CX Awards 2024 is here for its fourth year and is bigger and better than ever before! Winners of the 2023 awards included Vonage, Calabrio, and UJET and more. Then, the ceremony included exclusive streams from our people winners, Jay Patel from Webex and Kimberley Wood from Ultimate. Yet, this year’s event featured many more CX leaders who shared their unique takes on the space.
Photo – https://mma.prnewswire.com/media/2373968/Invoca___CXToday___PR_Newswire_Image___2700x1080___v_1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/invoca-wins-cx-today-award-for-best-conversational-intelligence-solution-of-2024-launches-european-data-centre-and-adds-uk-sales-leader-302102358.html

Continue Reading

Artificial Intelligence

ASC Achieves Certification for Webex Calling

Published

on

asc-achieves-certification-for-webex-calling

ASC announces compliance recording and AI-driven analytics tool for Webex Calling
HÖSBACH, Germany, March 28, 2024 /PRNewswire/ — ASC Technologies, a leading provider of comprehensive recording and analytics tools, announces its successful certification for Webex Calling with Webex by Cisco, a leading provider of collaboration technologies powering hybrid work and customer experience. This certification distinguishes ASC as one of the few global vendors who are authorized to provide record capabilities for Webex Calling communications. This capability is essential for organizations in regulated industries that must adhere to strict compliance standards.

A key benefit of the ASC solution is the simple and fast configuration in the Webex Control Hub, which ensures a high level of user-friendliness. In addition, ASC enables the migration of on-premise solutions to the cloud by seamlessly transferring recordings to the cloud environment. This step enables organizations to accelerate their digital transformation and take advantage of cloud-based services. In addition, AI-driven analytics, powered by ASC’s solutions, help organizations gain a comprehensive view of their communications, enrich customer relationships, and streamline compliance and risk management processes.
“As a stable company that has been established in the market for 60 years, we see the certification for Webex Calling not only as a confirmation of our technological expertise, but also as a promise to our customers and partners,” says Dr. Gerald Kromer, CEO of ASC. “We are committed to providing innovative and reliable solutions that meet the demands of today’s communications technologies while ensuring our customers’ compliance requirements.”
This certification is a further milestone in ASC’s successful partnership with Cisco, which has already existed for 20 years. ASC will be exhibiting at Enterprise Connect in Gaylord Palms, and Cisco Live in Las Vegas, showcasing its innovative recording and analytics solutions and demonstrating the results of its collaboration with Cisco. These events offer a glimpse into how ASC’s solutions drive efficiency and insight.
About ASC
ASC is a worldwide leading provider of software and cloud solutions in the field of omni-channel recording, quality management, and analytics. Among our target groups are all companies that record their communications, especially financial service providers, contact centers, and public safety organizations. We offer solutions for recording as well as AI-based analysis and evaluation of all communications – with full flexibility as a cloud service, on-premise or as a hybrid solution. Headquartered in Germany with subsidiaries in 14 countries and experienced system integration partners in over 60 countries, ASC is the #1 Europe-based player in its industry.
About Webex by Cisco
Webex is a leading provider of cloud-based collaboration solutions which includes video meetings, calling, messaging, events, customer experience solutions like contact center and purpose-built collaboration devices. At Webex, we start with people and their experiences first. This focus on delivering inclusive collaboration experiences fuels our innovation, which leverages AI and Machine Learning, to remove the barriers of geography, language, personality, and familiarity with technology. Our solutions are underpinned with security and privacy by design. We work with the world’s leading business and productivity apps – delivered through a single application and interface. Learn more at webex.com.
Logo: https://mma.prnewswire.com/media/2003160/ASC_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/asc-achieves-certification-for-webex-calling-302102352.html

Continue Reading

Artificial Intelligence

WSPN and MathWallet Jointly Launch StableWallet, Pioneering AA Wallet for Web3

Published

on

wspn-and-mathwallet-jointly-launch-stablewallet,-pioneering-aa-wallet-for-web3

TORTOLA, British Virgin Islands, March 28, 2024 /PRNewswire/ — WSPN, a global digital payments leader providing transparent, fast, and efficient solutions leveraging distributed ledger technology, has partnered with leading Web3 wallet provider MathWallet to launch StableWallet – a groundbreaking new account abstraction (AA) wallet that represents a major advancement in the Web3 space. StableWallet provides enhanced security, convenience, and flexibility for managing digital assets across multiple blockchains.

“Through our partnership with MathWallet, we are proud to introduce StableWallet, leveraging pioneering AA technology to transform digital asset management,” said Raymond Yuan, Founder of WSPN. “StableWallet exemplifies our commitment to driving innovation in digital payments and the Web3 ecosystem.”
Account abstraction (AA) wallets represent a significant leap forward in the Web3 ecosystem, blurring the lines between traditional private key wallets and smart contract-based accounts. By integrating both functionalities, AA wallets enable users to define their wallets through programmable smart contracts, unlocking a realm of advanced features and customization options.
Leveraging the transformative power of Account Abstraction, StableWallet stands at the forefront of security innovation, offering unmatched protection through advanced programmable recovery mechanisms and robust multi-signature controls. Seamlessly blending security with convenience, StableWallet ensures a user-centric experience by automating gas fees, simplifying transactions, and providing limitless customization possibilities through deep integration of programmable smart contracts.
Beyond its pioneering security measures, StableWallet serves as a pivotal link between the Ethereum and Polygon ecosystems, facilitating effortless asset management across diverse chains through a unified cross-chain interface. At its debut, StableWallet boasts essential features such as native support for Ethereum and Polygon networks, flexibility in fee token options with WUSD and USDT, and the capacity for multi-chain crypto smart contract wallet functionalities.
“We are thrilled to partner with WSPN and jointly unveil StableWallet’s powerful capabilities,” said Eric, CTO of MathWallet. “By combining cutting-edge account abstraction technology with robust security features and cross-chain compatibility, StableWallet empowers users to explore the decentralized realm with unparalleled confidence.”
Looking ahead, StableWallet has an ambitious roadmap to roll out new capabilities that will further elevate the user experience. Upcoming features include daily free transfers, batch transactions with one-click execution, enterprise multi-signature smart wallets, and integration with collaboration platforms, etc. These additions, among others, will continuously expand StableWallet’s functionality to meet evolving user needs in the Web3 space.
Whether for a seasoned cryptocurrency enthusiast or a beginner to the blockchain world, StableWallet offers a powerful tool to revolutionize user experience of digital asset management. Stay tuned for upcoming feature releases and network expansions as WSPN and MathWallet continue to push the boundaries of Web3 technology.
About WSPN
WSPN is a global digital payments company that provides transparent, fast, and efficient digital payment solutions leveraging the latest technological advancements of Distributed Ledger Technology (“DLT”). We are dedicated to shaping seamless digital payment solutions for our global partners worldwide at the frontier of future digital payments and financial inclusion.
Worldwide USD (‘WUSD’), WSPN’s flagship USD stablecoin, is a fiat-collateralized stablecoin that is pegged to the U.S. Dollar at a 1:1 ratio. Dedicated to optimizing payment solutions for web3 users, WUSD empowers the real economy through secure, transparent, and licensed digital payments, spanning stablecoins, exchanges and cards, all geared for global expansion.
Learn more: www.wspn.io  | Twitter | LinkedIn 
About MathWallet
MathWallet is the Multichain Wallet for Web3 that enables token storage of over 150 chains including BTC, ETH, Polkadot, Cosmos, Filecoin, Solana, BNBChain, etc, supports cross-chain token bridges and multi-chain dApp store. Our investors include Fenbushi Capital, Binance Labs, Fundamental Labs, Multicoin Capital, NGC Ventures, Amber Group, 6Eagle Capital.
Visit mathwallet.org for more information.
Photo – https://mma.prnewswire.com/media/2373177/WSPN.jpg Logo – https://mma.prnewswire.com/media/2374095/4619577/Logo_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/wspn-and-mathwallet-jointly-launch-stablewallet-pioneering-aa-wallet-for-web3-302102350.html

Continue Reading

Trending